BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

In a recent adoptive cell therapy (ACT) clinical trial using autologous tumor-infiltrating lymphocytes (TILs) in patients with metastatic melanoma, we found an association between CD8(+) T cells expressing the inhibitory receptor B- and T-lymphocyte attenuator (BTLA) and clinical response. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Haymaker, Cara L, Wu, Richard C, Ritthipichai, Krit, Bernatchez, Chantale, Forget, Marie-Andrée, Chen, Jie Qing, Liu, Hui, Wang, Ena, Marincola, Francesco, Hwu, Patrick, Radvanyi, Laszlo G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570103/
https://www.ncbi.nlm.nih.gov/pubmed/26405566
http://dx.doi.org/10.1080/2162402X.2015.1014246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570103/
https://www.ncbi.nlm.nih.gov/pubmed/26405566
http://dx.doi.org/10.1080/2162402X.2015.1014246

Ejemplares similares